Common polymorphisms in FMO1 are associated with nicotine dependence

Pharmacogenetics and Genomics

Volumn 21, Issue 7, 2011, Pages 397-402

  Hinrichs, Anthony L ^a   Murphy, Sharon E ^b   Wang, Jen C ^a   Saccone, Scott ^a   Saccone, Nancy ^a   Steinbach, Joe Henry ^a   Goate, Alison ^a   Stevens, Victoria L ^c   Bierut, Laura J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

flavin monooxygenase 1; nicotine dependence; nicotine metabolism

Indexed keywords

CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; BRAIN; CATALYSIS; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; KIDNEY; KIDNEY METABOLISM; MAJOR CLINICAL STUDY; MALE; OXIDATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

EID: 79959800431     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328346886f     Document Type: Article

References (26)

1. WHO Report on the Global Tobacco Epidemic, 2008-The MPOWER package; 2008. http://www.who.int/tobacco/mpower/en/.
2. Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002; 24:163-171. (Pubitemid 34106747)
3. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68:35-43. (Pubitemid 30609825)
4. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49:57-71.
5. Bierut LJ, Madden PAF, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 2007; 16:24-35. (Pubitemid 46152542)
6. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PAF, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 2007; 16:36-49. (Pubitemid 46152543)
7. Stevens VL, Bierut LJ, Talbot JT,Wang JC, Sun J, Hinrichs AL, et al. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 2008; 17:3517-3525.
8. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991; 86:1119-1127.
9. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95:221-227. (Pubitemid 43093236)
10. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38:209-213. (Pubitemid 43177235)
11. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155:945-959. (Pubitemid 30397141)
12. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909. (Pubitemid 44141658)
13. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74:765-769. (Pubitemid 38420107)
14. Park SB, Jacob P, Benowitz NL, Cashman JR. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-10-oxide. Chem Res Toxicol 1993; 6:880-888. (Pubitemid 23351213)
15. Murphy SE, Raulinaitis V, Brown KM. Nicotine 50-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 2005; 33:1166-1173. (Pubitemid 41043760)
16. Phillips IR, Francois AA, Shephard EA. The flavin-containing monoooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. Current Pharmacogenomics 2007; 5:292-313. (Pubitemid 350268214)
17. Zhang J, Cashman JR. Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 2006; 34:19-26. (Pubitemid 43042642)
18. Bhagwat SV, Bhamre S, Boyd MR, Ravindranath V. Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain. Neuropsychopharmacology 1996; 15:133-142. (Pubitemid 26255160)
19. Kim YM, Ziegler DM. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 2000; 28:1003-1006. (Pubitemid 30612622)
20. Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005; 33:1446-1452. (Pubitemid 41323991)
21. Hernandez D, Janmohamed A, Chandan P, Omar BA, Phillips IR, Shephard EA. Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. Pharmacogenet Genomics 2009; 19:289-299.
22. Pé rez-Stable EJ, Herrera B, Jacob P, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998; 280:152-156. (Pubitemid 28498387)
23. Benowitz NL, Pé rez-Stable EJ, Herrera B, Jacob P. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94:108-115. (Pubitemid 34121290)
24. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42:448-453.
25. Liu JZ, Tozzi F,Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Metaanalysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 2010; 42:436-440.
26. The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42:441-447.